Differential qualitative responses to rivastigmine in APOE E4 carriers and noncarriers

Martin Farlow, R. Lane, S. Kudaravalli, Y. He

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

This retrospective analysis of two double-blind, placebo-controlled studies in patients with mild to moderately severe AD investigated the efficacy of rivastigmine 6-12 mg/day on cognitive outcomes in patients with or without the apolipoprotein (APOE) E4 allele. APOE data were collected from patients who consented to pharmacogenetic testing. Treatment differences within each subgroup were compared, using the Observed Case (OC) population. The APOE E4 and non-APOE E4 subgroups comprised 246 and 121 patients, respectively. Overall, APOE E4 noncarriers showed greater decline than carriers (P<0.05). However, at 26 weeks, placebo-treated APOE E4 patients declined 3.04 points below baseline on the cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-cog), and rivastigmine-treated patients improved by 1.67 points. Non-APOE E4 placebo-treated patients declined by 4.59 points and rivastigmine-treated patients declined by 0.48 points. Thus, non-APOE E4 carriers showed a less favorable course under either placebo or rivastigmine, but both genotype-defined subgroups showed quantitatively similar responses to therapy (both P<0.05 vs placebo).

Original languageEnglish
Pages (from-to)332-335
Number of pages4
JournalPharmacogenomics Journal
Volume4
Issue number5
DOIs
StatePublished - 2004

Fingerprint

Rivastigmine
Apolipoprotein E4
Placebos
Apolipoproteins

Keywords

  • Alzheimer's disease
  • Apolipoprotein E
  • Rivastigmine

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine
  • Genetics

Cite this

Differential qualitative responses to rivastigmine in APOE E4 carriers and noncarriers. / Farlow, Martin; Lane, R.; Kudaravalli, S.; He, Y.

In: Pharmacogenomics Journal, Vol. 4, No. 5, 2004, p. 332-335.

Research output: Contribution to journalArticle

Farlow, Martin ; Lane, R. ; Kudaravalli, S. ; He, Y. / Differential qualitative responses to rivastigmine in APOE E4 carriers and noncarriers. In: Pharmacogenomics Journal. 2004 ; Vol. 4, No. 5. pp. 332-335.
@article{494eaf75806a4e20885b2c1b5d2bd2c1,
title = "Differential qualitative responses to rivastigmine in APOE E4 carriers and noncarriers",
abstract = "This retrospective analysis of two double-blind, placebo-controlled studies in patients with mild to moderately severe AD investigated the efficacy of rivastigmine 6-12 mg/day on cognitive outcomes in patients with or without the apolipoprotein (APOE) E4 allele. APOE data were collected from patients who consented to pharmacogenetic testing. Treatment differences within each subgroup were compared, using the Observed Case (OC) population. The APOE E4 and non-APOE E4 subgroups comprised 246 and 121 patients, respectively. Overall, APOE E4 noncarriers showed greater decline than carriers (P<0.05). However, at 26 weeks, placebo-treated APOE E4 patients declined 3.04 points below baseline on the cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-cog), and rivastigmine-treated patients improved by 1.67 points. Non-APOE E4 placebo-treated patients declined by 4.59 points and rivastigmine-treated patients declined by 0.48 points. Thus, non-APOE E4 carriers showed a less favorable course under either placebo or rivastigmine, but both genotype-defined subgroups showed quantitatively similar responses to therapy (both P<0.05 vs placebo).",
keywords = "Alzheimer's disease, Apolipoprotein E, Rivastigmine",
author = "Martin Farlow and R. Lane and S. Kudaravalli and Y. He",
year = "2004",
doi = "10.1038/sj.tpj.6500267",
language = "English",
volume = "4",
pages = "332--335",
journal = "Pharmacogenomics Journal",
issn = "1470-269X",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Differential qualitative responses to rivastigmine in APOE E4 carriers and noncarriers

AU - Farlow, Martin

AU - Lane, R.

AU - Kudaravalli, S.

AU - He, Y.

PY - 2004

Y1 - 2004

N2 - This retrospective analysis of two double-blind, placebo-controlled studies in patients with mild to moderately severe AD investigated the efficacy of rivastigmine 6-12 mg/day on cognitive outcomes in patients with or without the apolipoprotein (APOE) E4 allele. APOE data were collected from patients who consented to pharmacogenetic testing. Treatment differences within each subgroup were compared, using the Observed Case (OC) population. The APOE E4 and non-APOE E4 subgroups comprised 246 and 121 patients, respectively. Overall, APOE E4 noncarriers showed greater decline than carriers (P<0.05). However, at 26 weeks, placebo-treated APOE E4 patients declined 3.04 points below baseline on the cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-cog), and rivastigmine-treated patients improved by 1.67 points. Non-APOE E4 placebo-treated patients declined by 4.59 points and rivastigmine-treated patients declined by 0.48 points. Thus, non-APOE E4 carriers showed a less favorable course under either placebo or rivastigmine, but both genotype-defined subgroups showed quantitatively similar responses to therapy (both P<0.05 vs placebo).

AB - This retrospective analysis of two double-blind, placebo-controlled studies in patients with mild to moderately severe AD investigated the efficacy of rivastigmine 6-12 mg/day on cognitive outcomes in patients with or without the apolipoprotein (APOE) E4 allele. APOE data were collected from patients who consented to pharmacogenetic testing. Treatment differences within each subgroup were compared, using the Observed Case (OC) population. The APOE E4 and non-APOE E4 subgroups comprised 246 and 121 patients, respectively. Overall, APOE E4 noncarriers showed greater decline than carriers (P<0.05). However, at 26 weeks, placebo-treated APOE E4 patients declined 3.04 points below baseline on the cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-cog), and rivastigmine-treated patients improved by 1.67 points. Non-APOE E4 placebo-treated patients declined by 4.59 points and rivastigmine-treated patients declined by 0.48 points. Thus, non-APOE E4 carriers showed a less favorable course under either placebo or rivastigmine, but both genotype-defined subgroups showed quantitatively similar responses to therapy (both P<0.05 vs placebo).

KW - Alzheimer's disease

KW - Apolipoprotein E

KW - Rivastigmine

UR - http://www.scopus.com/inward/record.url?scp=5044252173&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=5044252173&partnerID=8YFLogxK

U2 - 10.1038/sj.tpj.6500267

DO - 10.1038/sj.tpj.6500267

M3 - Article

VL - 4

SP - 332

EP - 335

JO - Pharmacogenomics Journal

JF - Pharmacogenomics Journal

SN - 1470-269X

IS - 5

ER -